AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology, Inc. effective March 16, 2018 and bearing Investment ID OPP1182112 Amendment Purpose: Reporting & Payment Schedule Change...Vir Biotechnology, Inc. • March 26th, 2020 • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
AMENDMENT NO. 1 TO THE COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • March 26th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment No. 1 to the Common Stock Issuance Agreement (“Amendment”) is made and entered into, effective as of December 17, 2019 (“Amendment Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation with offices at with an office at 499 Illinois Street, San Francisco, California 94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation located at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”). Each of Vir and Alnylam are referred to in this Amendment as a “Party” and together, the “Parties”.
AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology, Inc. effective March 16, 2018, as amended, and bearing Investment ID OPP1182112 Amendment Purpose: Reporting and Payment...Vir Biotechnology, Inc. • March 26th, 2020 • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
AMENDMENT NO. 2 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 26th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment No. 2 to the Collaboration and License Agreement (“Amendment”) is made and entered into, effective as of March 3, 2020 (“Amendment No. 2 Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation with offices at with an office at 499 Illinois Street, San Francisco, California 94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation located at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”). Each of Vir and Alnylam are referred to in this Amendment as a “Party” and together, the “Parties”.
OPP1187970, Amendment 1 to Vir BiotechnologyVir Biotechnology, Inc. • March 26th, 2020 • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
AMENDMENT 2Grant Agreement • March 26th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of last signature. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
AMENDMENT NO. 1 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 26th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to the Collaboration and License Agreement (“Amendment”) is made and entered into, effective as of December 17, 2019 (“Amendment Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation with offices at with an office at 499 Illinois Street, San Francisco, California 94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation located at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”). Each of Vir and Alnylam are referred to in this Amendment as a “Party” and together, the “Parties”.
March 13, 2020 Michael Kamarck, PhDLetter Agreement • March 26th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
